Neuroplast

Neuroplast is a Dutch biotech advancing Neuro-Cells®, a proprietary autologous stem cell therapy targeting the shared pathways of neurodegeneration in conditions like spinal cord injury and dementia. The company is clinical-stage, leveraging orphan drug designations for regulatory acceleration in a multi-billion euro market with high unmet need. Its scalable platform and strong IP position it to potentially transform care for millions of patients lacking effective treatments.

Neuro-Cells®, a proprietary autologous stem cell platform using 'untouched' patient-derived cells designed to modulate neuroinflammation and promote repair across multiple neurodegenerative conditions.

Neuroplast competes in the rapidly evolving field of cell and gene therapies for neurological disorders, facing rivals developing both autologous and allogeneic stem cell therapies, gene therapies, and novel biologics. Its differentiation hinges on its 'untouched' autologous approach and platform strategy targeting shared disease pathways. Larger, well-capitalized companies pose significant competitive threats in terms of development speed and commercialization reach.